{"id":"NCT02690207","sponsor":"GlaxoSmithKline","briefTitle":"Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.","officialTitle":"Cross-vaccination Study of GSK Biologicals' Lyophilized Formulation of the Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-16","primaryCompletion":"2019-03-15","completion":"2019-03-15","firstPosted":"2016-02-24","resultsPosted":"2020-03-12","lastUpdate":"2021-03-04"},"enrollment":8687,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"Herpes Zoster Vaccine GSK1437173A","otherNames":["HZ/su"]}],"arms":[{"label":"HZ/su Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects \\>= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229).","primaryOutcome":{"measure":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)","timeFrame":"During 30 days (Days 0-29) after any vaccination (across doses)","effectByArm":[{"arm":"HZ/su Group","deltaMin":5175,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":195,"countries":["United States","Australia","Brazil","Canada","Czechia","Estonia","Finland","France","Germany","Hong Kong","Italy","Japan","Mexico","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["33277059"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":734,"n":8687},"commonTop":["Injection site pain","Injection site erythema","Pyrexia","Injection site swelling","Headache"]}}